Head-to-head · WeighScore
Oak vs Gala Health
The verdict
Gala Health takes it — 86/100 to 75.9/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.
We may earn a commission if you start care through some of these links, at no extra cost to you. Affiliate partners are listed first — a capped 3-point edge in board order only. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Oak | Gala Health |
|---|---|---|
| WeighScore | 75.9/100 | 86/100 |
| Grade | C | B |
| Scorecard rank | #40 | #10 |
| Semaglutide | From $119/mo | Not disclosed |
| Tirzepatide | From $185/mo | $179/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #40 · C
Strengths
- Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
- One price across every dosage, so titrating up costs no more
- No membership or subscription fee, and free shipping
- All 50 states, offered in Spanish as well as English
Where it loses points
- Same-day approval with no video call means very little clinical contact before a prescription
- No published lab or monitoring programme
- Injection only, and no brand-name lane
- Sold as packages, so re-ordering is on you
Graded #10 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 43 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.